Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Ajithkumar Sukumaran"'
Autor:
David J. Pinato, Alessio Cortellini, Ajithkumar Sukumaran, Tom Cole, Madhava Pai, Nagy Habib, Duncan Spalding, Mikael H. Sodergren, Maria Martinez, Tony Dhillon, Paul Tait, Robert Thomas, Caroline Ward, Hemant Kocher, Vincent Yip, Sarah Slater, Rohini Sharma
Publikováno v:
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Abstract Background After liver resection (LR), patients with hepatocellular cancer (HCC) are at high risk of recurrence. There are no approved anti-cancer therapies known to affect such risk, highlighting the acute need for novel systemic therapies
Externí odkaz:
https://doaj.org/article/598fe302c8354dada592676658cb5e13
Autor:
Sarah P. Blagden, David J. Harrison, Nigel W. McCracken, Essam Ghazaly, Hani Gabra, Ajithkumar Sukumaran, Chat Gnanaranjan, Laura Spiers, Rene L. Roux, Shibani Nicum, Farasat Kazmi
Fit of population PK model to observed plasma concentrations
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::0ec56fc7327723e59378cbd759a70e3f
https://doi.org/10.1158/1078-0432.22478298.v1
https://doi.org/10.1158/1078-0432.22478298.v1
Autor:
Sarah P. Blagden, David J. Harrison, Nigel W. McCracken, Essam Ghazaly, Hani Gabra, Ajithkumar Sukumaran, Chat Gnanaranjan, Laura Spiers, Rene L. Roux, Shibani Nicum, Farasat Kazmi
Purpose:NUC-1031 is a first-in-class ProTide modification of gemcitabine. In PRO-002, NUC-1031 was combined with carboplatin in recurrent ovarian cancer.Patients and Methods:NUC-1031 was administered on days 1 and 8 with carboplatin on day 1 every 3
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a2b5b4eebb189b3aefce230cee6f34e3
https://doi.org/10.1158/1078-0432.c.6529914.v1
https://doi.org/10.1158/1078-0432.c.6529914.v1
Autor:
Sarah P. Blagden, David J. Harrison, Nigel W. McCracken, Essam Ghazaly, Hani Gabra, Ajithkumar Sukumaran, Chat Gnanaranjan, Laura Spiers, Rene L. Roux, Shibani Nicum, Farasat Kazmi
Supplementary Methods and Tables
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::00c0d0ef4e3acfbc76b45a7ca5c62d2b
https://doi.org/10.1158/1078-0432.22478295
https://doi.org/10.1158/1078-0432.22478295
Autor:
Sarah P. Blagden, David J. Harrison, Nigel W. McCracken, Essam Ghazaly, Hani Gabra, Ajithkumar Sukumaran, Chat Gnanaranjan, Laura Spiers, Rene L. Roux, Shibani Nicum, Farasat Kazmi
Supplementary Legend
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c979b18044c01735fde9e4dae321583
https://doi.org/10.1158/1078-0432.22478292
https://doi.org/10.1158/1078-0432.22478292
Autor:
Pinato, David J., Cortellini, Alessio, Ajithkumar Sukumaran, Cole, Tom, Madhava Pai, Habib, Nagy, Spalding, Duncan, Sodergren, Mikael H., Martinez, Maria, Dhillon, Tony, Tait, Paul, Thomas, Robert, Ward, Caroline, Kocher, Hemant, Yip, Vincent, Slater, Sarah, Sharma, Rohini
Additional file 2.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::279cbe4ded9b121548739321a6bb7985
Autor:
Farasat Kazmi, Shibani Nicum, David J. Harrison, Hani Gabra, Ajithkumar Sukumaran, Chat Gnanaranjan, Nigel W McCracken, Laura Spiers, Sarah P. Blagden, Essam Ghazaly, Rene L Roux
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 27(11)
Purpose: NUC-1031 is a first-in-class ProTide modification of gemcitabine. In PRO-002, NUC-1031 was combined with carboplatin in recurrent ovarian cancer. Patients and Methods: NUC-1031 was administered on days 1 and 8 with carboplatin on day 1 every
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1e0d1429afbf8affaa948fb53509b0ce
https://pubmed.ncbi.nlm.nih.gov/33741651
https://pubmed.ncbi.nlm.nih.gov/33741651
Autor:
Maria Martinez, Madhava Pai, Tony Dhillon, Caroline Ward, Ajithkumar Sukumaran, Rohini Sharma, Paul Tait, Alessio Cortellini, David J. Pinato, Duncan Spalding, Robert Thomas, Sarah Slater, Tom Cole, Mikael H. Sodergren, Hemant M. Kocher, Nagy A. Habib, Vincent Yip
Publikováno v:
BMC Cancer
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
BMC Cancer, Vol 21, Iss 1, Pp 1-9 (2021)
Background After liver resection (LR), patients with hepatocellular cancer (HCC) are at high risk of recurrence. There are no approved anti-cancer therapies known to affect such risk, highlighting the acute need for novel systemic therapies to contro
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1752a2e9111001928ff4cc1c3864f285
https://pubmed.ncbi.nlm.nih.gov/33757459
https://pubmed.ncbi.nlm.nih.gov/33757459
Autor:
Robert C. F. Leonard, Laura Spiers, Puvan Suppiah, Nishat Bharwani, Markand Patel, Daniel O'Shea, Andrea Rockall, Ajithkumar Sukumaran, Sarah P. Blagden, Harpreet Wasan, Hani Gabra, Ivana Rizzuto, Mona El-Bahrawy, Nagy A. Habib, Essam Ghazaly
Publikováno v:
British Journal of Cancer
Background Gemcitabine is used to treat a wide range of tumours but its efficacy is limited by cancer cell resistance mechanisms. NUC-1031, a phosphoramidate modification of gemcitabine, is the first anti-cancer ProTide to enter the clinic and is des
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c7fd07a64e177af4a000c09ed3ff39c
http://europepmc.org/articles/PMC6189138
http://europepmc.org/articles/PMC6189138
Autor:
John Bridgewater, Andre Lopes, Sandra Beare, Marian Duggan, Dymphna Lee, Maravic Ricamara, Delyth McEntee, Ajithkumar Sukumaran, Harpreet Wasan, Juan W. Valle
Publikováno v:
BMC Cancer. 16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::186897c594b6c02883172fa66d9ecf6f
https://doi.org/10.1186/s12885-016-2403-1
https://doi.org/10.1186/s12885-016-2403-1